| 1 | 16326921 | S-adenosyl-L-homocysteine hydrolase inactivation curtails ovalbumin-induced immune responses. | J Pharmacol Exp Ther | 2006 Mar |
6 |
| 2 | 16914558 | A reversible S-adenosyl-L-homocysteine hydrolase inhibitor ameliorates experimental autoimmune encephalomyelitis by inhibiting T cell activation. | J Pharmacol Exp Ther | 2006 Nov |
9 |
| 3 | 21515785 | An endogenously anti-inflammatory role for methylation in mucosal inflammation identified through metabolite profiling. | J Immunol | 2011 Jun 1 |
1 |
| 4 | 23583916 | Critical role of transmethylation in TLR signaling and systemic lupus erythematosus. | Clin Immunol | 2013 May |
1 |
| 5 | 24374810 | Therapeutic effects of DZ2002, a reversible SAHH inhibitor, on lupus-prone NZB×NZW F1 mice via interference with TLR-mediated APC response. | Acta Pharmacol Sin | 2014 Feb |
17 |
| 6 | 29155016 | Topical administration of reversible SAHH inhibitor ameliorates imiquimod-induced psoriasis-like skin lesions in mice via suppression of TNF-α/IFN-γ-induced inflammatory response in keratinocytes and T cell-derived IL-17. | Pharmacol Res | 2018 Mar |
15 |
| 7 | 30696480 | Reversible SAHH inhibitor protects against glomerulonephritis in lupus-prone mice by downregulating renal α-actinin-4 expression and stabilizing integrin-cytoskeleton linkage. | Arthritis Res Ther | 2019 Jan 29 |
9 |
| 8 | 30740254 | Assay development for determination of DZ2002, a new reversible SAHH inhibitor, and its acid metabolite DZA in blood and application to rat pharmacokinetic study. | J Pharm Anal | 2019 Feb |
3 |
| 9 | 33412493 | DZ2002 alleviates psoriasis-like skin lesions via differentially regulating methylation of GATA3 and LCN2 promoters. | Int Immunopharmacol | 2021 Feb |
10 |
| 10 | 33437781 | Inhibition of S-adenosyl-L-homocysteine hydrolase alleviates alloimmune response by down-regulating CD4<sup>+</sup> T-cell activation in a mouse heart transplantation model. | Ann Transl Med | 2020 Dec |
1 |